Heterocyclic compounds and uses thereof
The present invention relates to pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment and/or prevention of a proliferation disorder, a cancer, a tumor, an inflammatory disease, an autoimmune disease, psoriasis, dry eye or an immunologically related disease, and in some embodiments diseases or disorders related to the dysregulation of kinase such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, FLT3(D835Y), ITK, TEC, TXK, BTK, or JAK, and the respective pathways.
1. A compound of Formula (Ia):
wherein
R 1 is NR c R d wherein
R c is a 3-7 member cyclic ring, said 3-7 member cyclic ring being optionally substituted with C 1-4 alkyl that is further optionally substituted with OZ or NR 11 R 12 , wherein Z, R 11 , R 12 are independently H or C 1-4 alkyl, or said 3-7 member cyclic ring being optionally substituted with SO 2 (CH 2 ) q H, wherein q is 1-4, or said 3-7 member cyclic ring being optionally substituted with C 1-4 alkyl that is further optionally substituted with SO 2 (CH 2 ) q H, wherein q is 1-4, or said 3-7 member cyclic ring being optionally substituted with R 8 CO, wherein R 8 is C 1-4 alkyl, and
R d is H, C 1-4 alkyl, C 1-4 alkenyl, or 3-7 member cyclic ring, said C 1-4 alkyl, C 1-4 alkenyl or 3-7 member cyclic ring being optionally substituted with OZ or NR 11 R 12 , wherein Z, R 11 , R 12 are independently H or C 1-4 alkyl;
R 2 is absent, H, halo, C 1-4 alkyl, C 1-4 alkoxy, or alkylamine (NR 11 R 12 ), wherein R 11 and R 12 are independently H or C 1-4 alkyl;
R 3 is H, hydroxyl, halo, C 1-4 alkyl, C 1-4 alkoxy, or alkylamine (NR 11 R 12 ), wherein R 11 and R 12 are independently H or C 1-4 alkyl;
R 5 is absent, H, halo, C 1-4 alkyl, C 1-4 alkoxy, or alkylamine (NR 11 R 12 ), wherein R 11 and R 12 are independently H or C 1-4 alkyl;
R 6 is H, halo, C 1-4 alkyl, C 1-4 alkoxy; or alkylamine (NR 11 R 12 ), wherein R 11 and R 12 are independently H or C 1-4 alkyl;
R 7 is H, halo, C 1-4 alkyl, C 1-4 alkoxy, or alkylamine (NR 11 R 12 ), wherein R 11 and R 12 are independently H or C 1-4 alkyl;
R 9 is H, hydroxyl, halo, C 1-4 alkyl, C 1-4 alkoxy, or alkylamine (NR 11 R 12 ), wherein R 11 and R 12 are independently H or C 1-4 alkyl;
R 10 is H, hydroxyl, halo, C 1-4 alkyl, C 1-4 alkoxy, or alkylamine (NR 11 R 12 ), wherein R 11 and R 12 are independently H or C 1-4 alkyl; or
R 2 and R 6 are part of 3-7 member cyclic ring, optionally substituted with C 1-4 alkyl optionally substituted with OZ or NR 11 R 12 wherein Z, R 11 and R 12 are independently H or C 1-4 alkyl;
R 4 is C 2 alkenyl optionally substituted with C 1-4 alkyl, —CH 2 OCH 3 , or —CH 2 N(CH 3 ) 2 ;
X is O, C 1-4 alkyl optionally substituted with halo, or NR b , wherein R b is H, or C 1-8 alkyl optionally substituted with halo;
Y is C, CH optionally substituted with halo, or N;
A is C, CH optionally substituted with halo or N; and
wherein at least one of R 2 , R 3 , R 5 and R 6 is not H;
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 , which is selected from the group consisting of compound I-42a, I-51a, I-53a, I-55a, I-57a, I-58a, I-60a, I-66a, and I-72a.
3. A pharmaceutical composition comprising a compound of claim 1 admixed with at least one pharmaceutically acceptable carrier or excipient.
4. The compound of claim 1 , wherein R c is H.
5. The compound of claim 1 , wherein R 1 is selected from the group consisting of
R a is C 2-4 alkyl optionally substituted with C 1-4 alkoxy or SO 2 (CH 2 ) q H, wherein q is 1-4, or R a is R 8 CO, wherein R 8 is C 1-4 alkyl, and
R b is H or C 1-4 alkyl optionally substituted with halo, C 1-4 alkoxy or SO 2 (CH 2 ) q H, wherein q is 1-4.
6. The compound of claim 1 , wherein Y is C, and R 2 is H or halo.
7. The compound of any claim 1 , wherein R 3 is C 1-4 alkoxy.
8. The compound of claim 1 , wherein A is C, and R 5 is H.
9. The compound of claim 1 , wherein R 9 is H.
10. The compound of claim 1 , wherein R 4 is unsubstituted C 2 alkenyl.
11. The compound of claim 1 , wherein X is O.
12. The compound of claim 1 , wherein R c is a 5 member cyclic ring.
13. The compound of claim 12 , wherein R c is a heterocyclic ring.
14. The compound of claim 13 , wherein the heterocyclic ring comprises a N atom.